Form 4: CEO David Jorden Increases Stake in Nuo Therapeutics

Nuo Therapeutics CEO and CFO David Jorden acquired 13,245 shares of common stock at a weighted average price of $1.0952.

Summary

• David Jorden, serving as both CEO and CFO of Nuo Therapeutics, Inc., purchased 13,245 shares of common stock.
• The transaction occurred on June 5, 2026.
• The shares were acquired at a weighted average price of $1.0952 per share, with individual transaction prices ranging from $1.042 to $1.15.
• Following this acquisition, Mr. Jorden's total beneficial ownership in the company increased to 2,085,000 shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as executive insider buying typically reflects confidence in the company's direction.

Positives

• Insider confidence is demonstrated by the CEO and CFO increasing his equity position in the company.
• The purchase of 13,245 shares indicates management's commitment to the long-term value of the firm.

Negatives

• None identified in this filing.

Risks

• Market volatility may impact the value of the acquired shares.
• The purchase price was based on a range of market prices, reflecting potential fluctuations in liquidity.

Future Outlook

No specific forward-looking guidance was provided in this regulatory filing.

Management Comments

• The reporting person undertakes to provide full information regarding the number of shares purchased at each separate transaction price upon request.

Industry Context

StockSavvy.ai notes that insider buying by a dual-role executive (CEO/CFO) is generally viewed by the market as a positive signal regarding the company's internal financial health and future prospects.

Comparison to Industry Standards

• Insider buying is a standard practice for executives to align their interests with shareholders.
• The volume of shares purchased is relatively small compared to the total holdings of 2,085,000, suggesting a routine accumulation rather than a major strategic shift.

Stakeholder Impact

• Shareholders may perceive this as a sign of management confidence in the company's current valuation.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Nuo Therapeutics, AURX, Insider Trading, Form 4, David Jorden, Equity Acquisition